CDAK insider filings

Codiak BioSciences, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-03-30. Screen CDAK transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for CDAK between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Codiak BioSciences, Inc.

FiledFormInsiderReported transactionsSource
2023-03-304Howze Yalonda — See RemarksSale (S): 1,628 @ $0.20EDGAR
2023-03-304Sathyanarayanan Sriram — Chief Scientific OfficerSale (S): 11,762 @ $0.17EDGAR
2023-03-304Konstantinov Konstantin — Chief Technology OfficerSale (S): 7,432 @ $0.20 · Sale (S): 1,932 @ $0.20EDGAR
2023-03-304Barna Nicole — See RemarksSale (S): 5,373 @ $0.17 · Sale (S): 1,932 @ $0.17EDGAR
2023-03-304Bain Linda — Chief Financial OfficerSale (S): 13,412 @ $0.17EDGAR
2023-03-304WILLIAMS DOUGLAS E — President & CEO, DirectorSale (S): 41,667 @ $0.18EDGAR
2023-02-214Konstantinov Konstantin — Chief Technology OfficerOption exercise (M): 4,200 · Sale (S): 1,308 @ $2.21 · Option exercise (M): 4,200 · Sale (S): 1,391 @ $0.59 · Option exercise (M): 4,200 (derivative) @ $0 · Option exercise (M): 4,200 (derivative) @ $0EDGAR
2023-02-214Sathyanarayanan Sriram — Chief Scientific OfficerOption exercise (M): 7,350 · Sale (S): 2,283 @ $2.21 · Option exercise (M): 7,350 · Sale (S): 2,407 @ $0.59 · Option exercise (M): 7,350 (derivative) @ $0 · Option exercise (M): 7,350 (derivative) @ $0EDGAR
2023-02-214Haddock Jason — DirectorOption exercise (M): 8,750 · Option exercise (M): 8,750 (derivative) @ $0EDGAR
2023-02-214Barna Nicole — See RemarksOption exercise (M): 3,150 · Sale (S): 984 @ $2.21 · Option exercise (M): 3,150 · Sale (S): 1,274 @ $0.59 · Option exercise (M): 3,150 (derivative) @ $0 · Option exercise (M): 3,150 (derivative) @ $0EDGAR
2023-02-214Howze Yalonda — See RemarksOption exercise (M): 4,857 · Sale (S): 1,512 @ $2.21 · Option exercise (M): 4,856 · Sale (S): 1,603 @ $0.59 · Option exercise (M): 4,857 (derivative) @ $0 · Option exercise (M): 4,856 (derivative) @ $0EDGAR
2023-02-214Bernstein Karen — DirectorOption exercise (M): 8,750 · Option exercise (M): 8,750 (derivative) @ $0EDGAR
2023-02-214Bain Linda — Chief Financial OfficerOption exercise (M): 7,613 · Sale (S): 2,364 @ $2.21 · Option exercise (M): 7,613 · Sale (S): 2,570 @ $0.59 · Option exercise (M): 7,613 (derivative) @ $0 · Option exercise (M): 7,613 (derivative) @ $0EDGAR
2023-02-214GILLIS STEVEN — DirectorOption exercise (M): 8,750 · Option exercise (M): 8,750 (derivative) @ $0EDGAR
2023-02-214MELAS KYRIAZI THEO — DirectorOption exercise (M): 8,750 · Option exercise (M): 8,750 (derivative) @ $0EDGAR
2023-02-214WILLIAMS DOUGLAS E — President & CEO, DirectorOption exercise (M): 22,969 · Sale (S): 7,112 @ $2.21 · Option exercise (M): 22,969 · Sale (S): 7,681 @ $0.59 · Option exercise (M): 22,969 (derivative) @ $0 · Option exercise (M): 22,969 (derivative) @ $0EDGAR
2023-02-214COONEY CHARLES L — DirectorOption exercise (M): 8,750 · Option exercise (M): 8,750 (derivative) @ $0EDGAR
2023-01-264Sathyanarayanan Sriram — Chief Scientific OfficerGrant/award (A): 140,000 (derivative) @ $0EDGAR
2023-01-264Konstantinov Konstantin — Chief Technology OfficerGrant/award (A): 145,000 (derivative) @ $0EDGAR
2023-01-264Howze Yalonda — See RemarksGrant/award (A): 150,000 (derivative) @ $0EDGAR
2023-01-264Barna Nicole — See RemarksGrant/award (A): 105,000 (derivative) @ $0EDGAR
2023-01-264Mauro David J — Chief Medical OfficerGrant/award (A): 190,000 (derivative) @ $0EDGAR
2023-01-264Bain Linda — Chief Financial OfficerGrant/award (A): 185,000 (derivative) @ $0EDGAR
2023-01-264WILLIAMS DOUGLAS E — President & CEO, DirectorGrant/award (A): 465,000 (derivative) @ $0EDGAR
2023-01-234Konstantinov Konstantin — Chief Technology OfficerOption exercise (M): 2,800 · Sale (S): 1,069 @ $0.58 · Option exercise (M): 2,800 (derivative) @ $0EDGAR
2023-01-234Sathyanarayanan Sriram — Chief Scientific OfficerOption exercise (M): 2,834 · Sale (S): 1,082 @ $0.58 · Option exercise (M): 2,834 (derivative) @ $0EDGAR
2023-01-234Howze Yalonda — See RemarksOption exercise (M): 4,000 · Sale (S): 1,512 @ $0.58 · Option exercise (M): 4,000 (derivative) @ $0EDGAR
2023-01-234Barna Nicole — See RemarksOption exercise (M): 2,167 · Sale (S): 836 @ $0.57 · Option exercise (M): 2,167 (derivative) @ $0EDGAR
2023-01-234Bain Linda — Chief Financial OfficerOption exercise (M): 5,000 · Sale (S): 1,880 @ $0.57 · Option exercise (M): 5,000 (derivative) @ $0EDGAR
2023-01-234WILLIAMS DOUGLAS E — See Remarks, DirectorOption exercise (M): 13,667 · Sale (S): 5,075 @ $0.57 · Option exercise (M): 13,667 (derivative) @ $0EDGAR
2022-09-204Sathyanarayanan Sriram — Chief Scientific OfficerGrant/award (A): 80,000 (derivative) @ $0EDGAR
2022-09-204Konstantinov Konstantin — Chief Technology OfficerGrant/award (A): 80,000 (derivative) @ $0EDGAR
2022-09-204Barna Nicole — See RemarksGrant/award (A): 80,000 (derivative) @ $0EDGAR
2022-09-204Howze Yalonda — See RemarksGrant/award (A): 80,000 (derivative) @ $0EDGAR
2022-09-204Mauro David J — Chief Medical OfficerGrant/award (A): 80,000 (derivative) @ $0EDGAR
2022-09-204Bain Linda — Chief Financial OfficerGrant/award (A): 80,000 (derivative) @ $0EDGAR
2022-09-164Flagship Ventures Fund V General Partner LLC — 10% owner
Flagship Ventures Fund V, L.P. — 10% owner
Flagship V VentureLabs Rx Fund, L.P. — 10% owner
AFEYAN NOUBAR — 10% owner
Purchase (P): 722,590 · Purchase (P): 210,743 · Purchase (P): 722,590 (derivative) · Purchase (P): 210,743 (derivative)EDGAR
2022-09-154GILLIS STEVEN — DirectorPurchase (P): 5,000,000 · Purchase (P): 5,000,000 (derivative)EDGAR
2022-09-154ARCH Venture Fund VIII, L.P. — 10% owner
ARCH Venture Fund VIII Overage, L.P. — 10% owner
CRANDELL KEITH — 10% owner
BYBEE CLINTON — 10% owner
NELSEN ROBERT — 10% owner
ARCH Venture Partners VIII, LLC — 10% owner
ARCH Venture Partners VIII, L.P. — 10% owner
Purchase (P): 5,000,000 @ $1.50 · Purchase (P): 5,000,000 (derivative)EDGAR
2022-06-214Haddock Jason — DirectorGrant/award (A): 7,500 (derivative) @ $0 · Grant/award (A): 1,500 (derivative) @ $0EDGAR
2022-06-214Eggimann Anne-Virginie — DirectorGrant/award (A): 7,500 (derivative) @ $0 · Grant/award (A): 1,500 (derivative) @ $0EDGAR
2022-06-214Pandite Arundathy N. — DirectorGrant/award (A): 7,500 (derivative) @ $0 · Grant/award (A): 1,500 (derivative) @ $0EDGAR
2022-06-214Bernstein Karen — DirectorGrant/award (A): 7,500 (derivative) @ $0 · Grant/award (A): 1,500 (derivative) @ $0EDGAR
2022-06-214GILLIS STEVEN — DirectorGrant/award (A): 7,500 (derivative) @ $0 · Grant/award (A): 1,500 (derivative) @ $0EDGAR
2022-06-214MELAS KYRIAZI THEO — DirectorGrant/award (A): 7,500 (derivative) @ $0 · Grant/award (A): 1,500 (derivative) @ $0EDGAR
2022-06-214COONEY CHARLES L — DirectorGrant/award (A): 7,500 (derivative) @ $0 · Grant/award (A): 1,500 (derivative) @ $0EDGAR
2022-05-044Mauro David J — Chief Medical OfficerGrant/award (A): 200,000 (derivative) @ $0 · Grant/award (A): 20,000 (derivative) @ $0EDGAR
2022-02-184MELAS KYRIAZI THEO — DirectorGrant/award (A): 8,750 (derivative) @ $0EDGAR
2022-02-184WILLIAMS DOUGLAS E — President & CEO, DirectorGrant/award (A): 61,250 (derivative) @ $0 · Grant/award (A): 91,875 (derivative) @ $0EDGAR
2022-02-184COONEY CHARLES L — DirectorGrant/award (A): 8,750 (derivative) @ $0EDGAR

Recent 8-K events — Codiak BioSciences, Inc.

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2023-03-298-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2023-03-278-K1.03 — Bankruptcy or Receivership
?
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2022-11-038-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2022-09-148-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2022-08-308-K?
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2022-08-048-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2022-06-308-K7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2022-06-298-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2022-06-218-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2022-05-058-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=CDAK returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs